Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00406172
First received: November 30, 2006
Last updated: December 4, 2006
Last verified: November 2006
  Purpose

To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.


Condition Intervention Phase
Cystoid Macular Edema
Drug: Bevacizumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Pseudophakic eyes with macular edema

Exclusion Criteria:

  • Other retinopathies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406172

Contacts
Contact: Victoria Cubas-Lorenzo, MD (55) 10841400 ext 1171 retinamex@yahoo.com

Locations
Mexico
APEC Recruiting
México D.F., Mexico, 03040
Contact: Victoria Cubas-Lorenzo, MD    (55) 10841400 ext 1171    retinamex@yahoo.com   
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Victoria Cubas-Lorenzo, MD APEC México
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00406172     History of Changes
Other Study ID Numbers: APEC 0016
Study First Received: November 30, 2006
Last Updated: December 4, 2006
Health Authority: México: Secretaría de Salubridad

Additional relevant MeSH terms:
Edema
Macular Edema
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Signs and Symptoms
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014